O. Hansson

Global and regional amyloid-β in explaining APOE-ε4 and sex associations with medial temporal tau: a neuropathology study

Different functional connectivity gradients reflect aging and Alzheimer's disease.

It is shown that functional connectivity changes associated with aging and AD are strongly aligned with separate fundamental axes of hierarchical brain communication, which suggest that both AD and aging alter major but orthogonal functional pathways in the brain.

Comparison of quantitative digital and semiquantitative assessments of tau pathology in relation to regional in vivo tau PET.

Quantitative digital image analysis has emerged as a powerful tool for assessing neuropathological burden. Although previous studies have compared quantitative digital and semiquantitative pathology measures, their respective relationships with regionally corresponding in vivo tau PET measures remain poorly characteriz...

Plasma Biomarkers for Neocortical Tau Burden.

This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals, suggesting a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or resear...

Plasma P‐tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease

This analysis of the phase 3 TRAILBLAZER‐ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p‐tau217) level can reliably monitor treatment‐related amyloid clearance (TRAC) after donanemab treatment in early symptomatic Alzheimer's disease (AD).

Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial

A phase 1/2 trial of an off-the-shelf stem cell-derived dopaminergic progenitor therapy demonstrated a favorable 12-month safety profile, with no graft-related adverse events, dyskinesias or tumor formation, although risks were associated with the immunosuppression regimen.

CSF p-tau205: a biomarker of Alzheimer's disease progression and biological staging.

CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk...

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

A double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use, and positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads).